Rhynchophylline Reverses Obesity in High-Fat Diet-Induced Obese Rats by Regulating the Inflammatory Cascade and Blocking 3‑hydroxy-3-methylglutaryl Coenzyme A Reductase.

Obesity is a metabolic disorder that could be the reason for the development of several disorders, and its management is necessary. The investigation evaluated the beneficial effect of rhynchophylline on high-fat diet (HFD)-induced obese rats. Obesity was induced with the HFD for 4 weeks, and rhynchophylline at 50 and 100 mg/kg was administered intraperitoneally (i.p.) for the next 4 weeks in the respective groups. Blood glucose and lipid profiles were estimated in rhynchophylline-treated HFD-induced obese rats. Levels of cytokines, reactive oxygen species (ROS), and oxidative stress parameters were estimated in the liver tissue and blood of all the groups of rats. The weight of adipose tissue and other organs, such as the liver and pancreas, was measured in the rats. The binding affinity of rhynchophylline with 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase, ) was estimated through a docking study. Treatment with rhynchophylline ameliorated the altered levels of glucose and lipid profiles in the serum of the obese rats. The weight of adipose tissue isolated from different regions of the body was reduced in the rhynchophylline-treated group compared to that in the obese group. There was a significant reduction of oxidative stress in the rhynchophylline-treated group compared with the obese group of rats. The in silico study showed that rhynchophylline binds with HMG-CoA reductase with a binding energy of -8.37 kcal/mol. In conclusion, data from the report reveal that rhynchophylline reduces obesity by promoting the conversion of white adipose tissue (WAT) to brown adipose tissue (BAT), as it interacts with HMG-CoA reductase in HFD-induced obese rats.